SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for CDT Equity Inc. (CDT, CDTTW) (CIK 0001896212) (CDT) — Feb 6, 2026

CDT Equity Inc. (CDT, CDTTW) (CIK 0001896212)
Date: Feb. 6, 2026 · CIK: 0001896212 · Accession: 0000000000-26-001264

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-293062

Date
February 6, 2026
Author
Jamie Bligh
Form
UPLOAD
Company
CDT Equity Inc. (CDT, CDTTW) (CIK 0001896212)

Letter

February 6, 2026 Jamie Bligh Chief Financial Officer CDT Equity Inc. 4851 Tamiami Trail North, Suite 200 Naples, Florida 34103 Re:CDT Equity Inc. Registration Statement on Form S-3 Filed January 30, 2026 File No. 333-293062 Dear Jamie Bligh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Todd Mason

Show Raw Text
February 6, 2026
Jamie Bligh
Chief Financial Officer
CDT Equity Inc.
4851 Tamiami Trail North, Suite 200
Naples, Florida 34103
Re:CDT Equity Inc.
Registration Statement on Form S-3
Filed January 30, 2026
File No. 333-293062
Dear Jamie Bligh:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Todd Mason